The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jourdan, M.
Right arrow Articles by Klein, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jourdan, M.
Right arrow Articles by Klein, B.

The Journal of Immunology, Vol 147, Issue 12 4402-4407, Copyright © 1991 by American Association of Immunologists


ARTICLES

IFN-alpha induces autocrine production of IL-6 in myeloma cell lines

M Jourdan, XG Zhang, M Portier, JM Boiron, R Bataille and B Klein
INSERM U 291, Immunopathologie des Maladies Tumorales et Autoimmunes, Montpellier, France.

IL-6 is a major tumor growth factor in human multiple myeloma. Myeloma cell lines, which have the same phenotypic characteristics and Ig gene rearrangements as the original fresh myeloma cells and whose growth is strictly dependent on exogenous IL-6 similar to fresh myeloma cells, have been reproducibly established. We show here that IFN-alpha stimulated the growth of five of six of these human myeloma cell lines by inducing an autocrine production of IL-6 in myeloma cells. Indeed, IFN-alpha induced IL-6 mRNA accumulation and IL-6 production in myeloma cells and the IFN-alpha-induced growth of these cells was inhibited by anti-IL-6 mAb. Moreover, IFN-alpha made possible the rapid emergence of autonomously growing myeloma cell sublines, which produced IL-6 as an autocrine growth factor. As IFN-alpha has a potential therapeutical interest for multiple myeloma, the present study opens up new directions for studying its effects on the myeloma clone in vivo.


This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Condomines, P. Quittet, Z.-Y. Lu, L. Nadal, P. Latry, E. Lopez, M. Baudard, G. Requirand, C. Duperray, J.-F. Schved, et al.
Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor.
J. Immunol., June 1, 2006; 176(11): 6631 - 6639.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Moreaux, E. Legouffe, E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J.-F. Rossi, B. Klein, and K. Tarte
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
Blood, April 15, 2004; 103(8): 3148 - 3157.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. H. L. Ng, K. W. To, K. W. Lo, S. Chan, K. S. Tsang, S. H. Cheng, and H. K. Ng
Frequent Death-associated Protein Kinase Promoter Hypermethylation in Multiple Myeloma
Clin. Cancer Res., June 1, 2001; 7(6): 1724 - 1729.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Ogawa, T. Nishiura, K. Oritani, H. Yoshida, M. Yoshimura, Y. Okajima, J. Ishikawa, K. Hashimoto, I. Matsumura, Y. Tomiyama, et al.
Cytokines Prevent Dexamethasone-induced Apoptosis via the Activation of Mitogen-activated Protein Kinase and Phosphatidylinositol 3-Kinase Pathways in a New Multiple Myeloma Cell Line
Cancer Res., August 1, 2000; 60(15): 4262 - 4269.
[Abstract] [Full Text]


Home page
BloodHome page
P. Georgii-Hemming, T. Stromberg, E. T. Janson, M. Stridsberg, H. J. Wiklund, and K. Nilsson
The Somatostatin Analog Octreotide Inhibits Growth of Interleukin-6 (IL-6)-Dependent and IL-6-Independent Human Multiple Myeloma Cell Lines
Blood, March 1, 1999; 93(5): 1724 - 1731.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Spets, P. Georgii-Hemming, J. Siljason, K. Nilsson, and H. Jernberg-Wiklund
Fas/APO-1 (CD95)-Mediated Apoptosis Is Activated by Interferon-gamma and Interferon-alpha in Interleukin-6 (IL-6)-Dependent and IL-6-Independent Multiple Myeloma Cell Lines
Blood, October 15, 1998; 92(8): 2914 - 2923.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Ferlin-Bezombes, M. Jourdan, J. Liautard, J. Brochier, J.-F. Rossi, and B. Klein
IFN-{alpha} Is a Survival Factor for Human Myeloma Cells and Reduces Dexamethasone-Induced Apoptosis
J. Immunol., September 15, 1998; 161(6): 2692 - 2699.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J.-F. Rossi, J. Brochier, and B. Klein
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Blood, June 15, 1998; 91(12): 4727 - 4737.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood, January 1, 1998; 91(1): 3 - 21.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Vincent, M. Jourdan, M.-S. Sy, B. Klein, and N. Mechti
Hyaluronic Acid Induces Survival and Proliferation of Human Myeloma Cells through an Interleukin-6-mediated Pathway Involving the Phosphorylation of Retinoblastoma Protein
J. Biol. Chem., April 27, 2001; 276(18): 14728 - 14736.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1991 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1991 by The American Association of Immunologists, Inc. All rights reserved.